Denmark-based Novo Nordisk on Thursday launched its weekly basal insulin injection, Awiqli, in India, one of the countries with the highest diabetes rates in the world.
The company says that Awiqli is the world’s first once-weekly basal, or background long-acting, insulin approved for clinical use and will be indicated for type 1 and type 2 diabetes in adults, potentially facing rivalry from existing daily dose options in the market.
-copy-29e15046.jpeg?w=600)
